Pharmaceuticals, Biotechnology and Life Sciences
Hikma Pharmaceuticals has announced it launched Micafungin for Injection through its US affiliate, Hikma Pharmaceuticals USA Inc. The company has launched 50mg and 100mg doses.
The drug maker Merck said it plans to seek emergency use authorization in the U.S. as soon as possible and to submit applications to regulatory agencies worldwide for Molnupiravir, which could be the first oral antiviral medicine for COVID-19.
Cellbox Solutions GmbH, developer of the patented Cellbox technology, has founded their U.S. company and is now selling products directly to the U.S./North American market.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine.
Initial up-front endowment of $50 million Foundation to support charitable organizations and causes that promote public health, healthcare and educational…
Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B,…
Mupadolimab Phase 1/1b oncology clinical trial continues, with a focus on leveraging B cell activation and enhancement of anti-viral antibodies…
KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics…
Halozyme’s drug delivery technology provides the opportunity to administer large volume subcutaneous injections that may enable dosing intervals of every…
The European Commission regulatory approval is primarily supported by data from the ECZTRA 1, 2 and ECZTRA 3 pivotal Phase…